Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest acute promyelocytic leukemia Stories

2013-12-16 08:25:29

- Initial results for BL-8040 show substantial mobilization of cancer cells and signs of robust cancer cell death (apoptosis) - JERUSALEM, Dec. 16, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today promising initial results for its BL-8040 drug candidate in a Phase 2 clinical trial for patients with relapsed or refractory acute...

2013-11-13 08:28:56

Trisenox(®) is now available in Canada MONTREAL, Nov. 13, 2013 /CNW/ - Health Canada has recently approved Trisenox® (arsenic trioxide) for relapsed or refractory acute promyelocytic leukemia (APL). This was made possible by a decision from Health Canada's Therapeutic Products Directorate to remove a prior regulatory prohibition on arsenic containing drug therapies for use in humans and by granting priority review. Trisenox® has been available since 2000 for the treatment...

2013-01-25 12:25:13

WHITE PLAINS, N.Y., Jan. 25, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) has awarded Anand Jillella, M.D., Chief of Hematology, Oncology and Bone Marrow Transplant at the Georgia Regents University in Augusta, GA, with $1.68 million in funding from LLS's Therapy Acceleration Program (TAP). Dr. Jillella's proposal entitled "A Simple Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL)" will be funded over the next five years. The goal of...

2012-12-10 16:38:13

Research identifying genetic factors that affect survival of patients with blood cancers and evaluating the effectiveness of modified treatment strategies to improve outcomes while reducing toxicity will be presented today at the 54th Annual Meeting of the American Society of Hematology (ASH). While the cancer research community has seen many significant therapeutic advances over the last decade, only recently have investigators identified how patients' individual genetic makeup influences...

2012-12-08 12:20:19

ATLANTA, Dec. 8, 2012 /PRNewswire-USNewswire/ -- Research identifying genetic factors that affect survival of patients with blood cancers and evaluating the effectiveness of modified treatment strategies to improve outcomes while reducing toxicity will be presented today at the 54th Annual Meeting of the American Society of Hematology (ASH). While the cancer research community has seen many significant therapeutic advances over the last decade, only recently have investigators identified how...

2012-10-25 11:25:28

WOODCLIFF LAKE, N.J., Oct. 25, 2012 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that its operating subsidiary, Anchen Pharmaceuticals, Inc., has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for tretinoin capsules, 10 mg. Tretinoin capsules is the generic version of Vesanoid(®) capsules and is used in the treatment of acute promyelocytic leukemia. Par expects to begin shipping the product before the end...

2012-07-18 02:25:29

SAN DIEGO, July 18, 2012 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a developer of transrenal molecular diagnostics, received notice of U.S. Patent 8,222,370, titled "Nucleophosmin protein (NPM) mutants, corresponding gene sequences and uses thereof." This is the first U.S. patent issued around this mutation, and is part of a family of filed patents for Trovagene around NPM. Mutation analysis of nucleophosmin-1 (NPM1) is currently used for the diagnosis, stratification and monitoring of...

2011-05-19 14:03:17

Ray Johnston's goal in three years is for his band to sell out at the 1,600-seat House of Blues in Dallas. In eight years, he wants to pack the 6,400-seat Verizon Theatre in Grand Prairie, and by 2030, to play to tens of thousands of fans at Cowboys Stadium in Arlington. Mr. Johnston's unmentioned goal, though, is to live another year after battling leukemia for the past seven. Despite four relapses, the former Dallas Mavericks basketball player is enjoying life as a rising musician in The...

2010-12-23 02:11:54

Arsenic is usually thought of as a poison. Despite this, it has been used in medicine for over 2000 years, and the arsenic compound arsenic trioxide (ATO) is FDA approved for the treatment of acute promyelocytic leukemia. Now, a team of researchers, led by Aykut Ãœren, at Georgetown University Medical Center, Washington, has generated data using human cancer cell lines that suggest that ATO might also be of benefit to individuals with certain brain tumors or...

2010-11-11 22:12:22

Arsenic, a toxic compound with a reputation as a good tool for committing homicide, has a significant positive effect on the survival of patients with acute promyelocytic leukemia (APL), when administered after standard initial treatment, according to a new, multi-center study led by a researcher at Wake Forest University Baptist Medical Center. While arsenic trioxide (As2O3) is known by clinicians to be a highly effective treatment for patients with relapsed APL, its benefit earlier in...